ES2201: neoadjuvant nivo/ipi with radiotherapy in MSI-H/dMMR rectal tumors 

Kristen Ciombor, MD, MSCI, Vanderbilt-Ingram Cancer Center, Nashville, TN, discusses findings from the Phase II ES2201 trial (NCT04751370) of neoadjuvant nivolumab plus ipilimumab and short course radiation in microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR) rectal tumors. Pathological complete response, the primary endpoint, was promising, especially in patients who subsequently underwent surgery. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.